| Identification | Back Directory | [Name]
AMD 070 | [CAS]
558447-26-0 | [Synonyms]
AMD 070
AMD-11070
Mavorixafor
AMD070/AMD-070
Mavorixafor(AMD-070)
N-(1H-benzimidazol-2-ylmethyl)-N-[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]- (9CI)
AMD 070 N-(1H-benziMidazol-2-ylMethyl)-N-[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]- (9CI)
N'-(1H-Benzimidazol-2-ylmethyl)-N'-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine
1,4-ButanediaMine, N-(1H-benziMidazol-2-ylMethyl)-N-[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]-
N'-(1h-benzimidazol-2-ylmethyl)-n'-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine
1,4-Butanediamine, N1-(1H-benzimidazol-2-ylmethyl)-N1-[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]-
(S)-N1-((1H-Benzo[d]imidazol-2-yl)methyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diami
(S)-N1-((1H-benzo[d]iMidazol-2-yl)Methyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diaMine
Mavorixafor,CXCR,AMD 070,Human immunodeficiency virus,AMD070,HIV,inhibit,CXC chemokine receptors,Inhibitor | [Molecular Formula]
C21H27N5 | [MDL Number]
MFCD11977316 | [MOL File]
558447-26-0.mol | [Molecular Weight]
349.47 |
| Chemical Properties | Back Directory | [Melting point ]
108-110℃ | [Boiling point ]
597.0±50.0 °C(Predicted) | [density ]
1.21 | [storage temp. ]
Store at -20°C | [solubility ]
≥17.45 mg/mL in DMSO; ≥44.5 mg/mL in EtOH; ≥7.47 mg/mL in H2O with gentle warming | [form ]
oil | [pka]
11.65±0.10(Predicted) | [color ]
brown |
| Hazard Information | Back Directory | [Uses]
N-(1H-Benzimidazol-2-ylmethyl)-N-[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]-1,4-butanediamine is a potent CXCR4 inhibitor that inhibits X4 HIV-1 replication and the gp120/CXCR4 interaction. It also has therapeutic potential for developing treatments for B-RAF wild-type and mutated melanomas. | [Definition]
ChEBI: AMD 070 is an aminoquinoline. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|